192 related articles for article (PubMed ID: 36765035)
1. A vector-encoded bispecific killer engager to harness virus-activated NK cells as anti-tumor effectors.
Floerchinger A; Klein JE; Finkbeiner MSC; Schäfer TE; Fuchs G; Doerner J; Zirngibl H; Ackermann M; Kvasnicka HM; Chester KA; Jäger D; Ball CR; Ungerechts G; Engeland CE
Cell Death Dis; 2023 Feb; 14(2):104. PubMed ID: 36765035
[TBL] [Abstract][Full Text] [Related]
2. Bispecific killer cell engager with high affinity and specificity toward CD16a on NK cells for cancer immunotherapy.
Nikkhoi SK; Li G; Eleya S; Yang G; Vandavasi VG; Hatefi A
Front Immunol; 2022; 13():1039969. PubMed ID: 36685519
[TBL] [Abstract][Full Text] [Related]
3. CD16xCD33 Bispecific Killer Cell Engager (BiKE) as potential immunotherapeutic in pediatric patients with AML and biphenotypic ALL.
Reusing SB; Vallera DA; Manser AR; Vatrin T; Bhatia S; Felices M; Miller JS; Uhrberg M; Babor F
Cancer Immunol Immunother; 2021 Dec; 70(12):3701-3708. PubMed ID: 34398302
[TBL] [Abstract][Full Text] [Related]
4. Bispecific immune cell engager enhances the anticancer activity of CD16+ NK cells and macrophages in vitro, and eliminates cancer metastasis in NK humanized NOG mice.
Khoshtinat Nikkhoi S; Yang G; Owji H; Grizotte-Lake M; Cohen RI; Gil Gonzalez L; Massumi M; Hatefi A
J Immunother Cancer; 2024 Mar; 12(3):. PubMed ID: 38490714
[TBL] [Abstract][Full Text] [Related]
5. Targeting natural killer cells to acute myeloid leukemia in vitro with a CD16 x 33 bispecific killer cell engager and ADAM17 inhibition.
Wiernik A; Foley B; Zhang B; Verneris MR; Warlick E; Gleason MK; Ross JA; Luo X; Weisdorf DJ; Walcheck B; Vallera DA; Miller JS
Clin Cancer Res; 2013 Jul; 19(14):3844-55. PubMed ID: 23690482
[TBL] [Abstract][Full Text] [Related]
6. Heterodimeric Bispecific Single Chain Variable Fragments (scFv) Killer Engagers (BiKEs) Enhance NK-cell Activity Against CD133+ Colorectal Cancer Cells.
Schmohl JU; Gleason MK; Dougherty PR; Miller JS; Vallera DA
Target Oncol; 2016 Jun; 11(3):353-61. PubMed ID: 26566946
[TBL] [Abstract][Full Text] [Related]
7. NK Cell Effector Functions and Bystander Tumor Cell Killing in Immunovirotherapy.
Floerchinger A; Engeland CE
Methods Mol Biol; 2022; 2521():233-248. PubMed ID: 35733001
[TBL] [Abstract][Full Text] [Related]
8. Enhanced ADCC and NK Cell Activation of an Anticarcinoma Bispecific Antibody by Genetic Insertion of a Modified IL-15 Cross-linker.
Schmohl JU; Felices M; Taras E; Miller JS; Vallera DA
Mol Ther; 2016 Aug; 24(7):1312-22. PubMed ID: 27157665
[TBL] [Abstract][Full Text] [Related]
9. Engineering of Anti-CD133 Trispecific Molecule Capable of Inducing NK Expansion and Driving Antibody-Dependent Cell-Mediated Cytotoxicity.
Schmohl JU; Felices M; Oh F; Lenvik AJ; Lebeau AM; Panyam J; Miller JS; Vallera DA
Cancer Res Treat; 2017 Oct; 49(4):1140-1152. PubMed ID: 28231426
[TBL] [Abstract][Full Text] [Related]
10. CD16xCD33 bispecific killer cell engager (BiKE) activates NK cells against primary MDS and MDSC CD33+ targets.
Gleason MK; Ross JA; Warlick ED; Lund TC; Verneris MR; Wiernik A; Spellman S; Haagenson MD; Lenvik AJ; Litzow MR; Epling-Burnette PK; Blazar BR; Weiner LM; Weisdorf DJ; Vallera DA; Miller JS
Blood; 2014 May; 123(19):3016-26. PubMed ID: 24652987
[TBL] [Abstract][Full Text] [Related]
11. Targeted BiTE Expression by an Oncolytic Vector Augments Therapeutic Efficacy Against Solid Tumors.
Speck T; Heidbuechel JPW; Veinalde R; Jaeger D; von Kalle C; Ball CR; Ungerechts G; Engeland CE
Clin Cancer Res; 2018 May; 24(9):2128-2137. PubMed ID: 29437789
[No Abstract] [Full Text] [Related]
12. IL15 Trispecific Killer Engagers (TriKE) Make Natural Killer Cells Specific to CD33+ Targets While Also Inducing Persistence, In Vivo Expansion, and Enhanced Function.
Vallera DA; Felices M; McElmurry R; McCullar V; Zhou X; Schmohl JU; Zhang B; Lenvik AJ; Panoskaltsis-Mortari A; Verneris MR; Tolar J; Cooley S; Weisdorf DJ; Blazar BR; Miller JS
Clin Cancer Res; 2016 Jul; 22(14):3440-50. PubMed ID: 26847056
[TBL] [Abstract][Full Text] [Related]
13. Bi-Specific Killer Cell Engager Enhances NK Cell Activity against Interleukin-13 Receptor Alpha-2 Positive Gliomas.
Pawlowski KD; Duffy JT; Tiwari A; Zannikou M; Balyasnikova IV
Cells; 2023 Jun; 12(13):. PubMed ID: 37443750
[TBL] [Abstract][Full Text] [Related]
14. Trispecific killer engager 161519 enhances natural killer cell function and provides anti-tumor activity against CD19-positive cancers.
Cheng Y; Zheng X; Wang X; Chen Y; Wei H; Sun R; Tian Z; Sun H
Cancer Biol Med; 2020 Nov; 17(4):1026-1038. PubMed ID: 33299651
[TBL] [Abstract][Full Text] [Related]
15. TriKEs and BiKEs join CARs on the cancer immunotherapy highway.
Tay SS; Carol H; Biro M
Hum Vaccin Immunother; 2016 Nov; 12(11):2790-2796. PubMed ID: 27322989
[TBL] [Abstract][Full Text] [Related]
16. Bispecific NK-cell engager targeting BCMA elicits stronger antitumor effects and produces less proinflammatory cytokines than T-cell engager.
Xiao X; Cheng Y; Zheng X; Fang Y; Zhang Y; Sun R; Tian Z; Sun H
Front Immunol; 2023; 14():1113303. PubMed ID: 37114050
[TBL] [Abstract][Full Text] [Related]
17. Natural Killer Cell Engagers (NKCEs): a new frontier in cancer immunotherapy.
Zhang M; Lam KP; Xu S
Front Immunol; 2023; 14():1207276. PubMed ID: 37638058
[TBL] [Abstract][Full Text] [Related]
18. Antigen-specific oncolytic MV-based tumor vaccines through presentation of selected tumor-associated antigens on infected cells or virus-like particles.
Hutzler S; Erbar S; Jabulowsky RA; Hanauer JRH; Schnotz JH; Beissert T; Bodmer BS; Eberle R; Boller K; Klamp T; Sahin U; Mühlebach MD
Sci Rep; 2017 Dec; 7(1):16892. PubMed ID: 29203786
[TBL] [Abstract][Full Text] [Related]
19. Natural killer cells unleashed: Checkpoint receptor blockade and BiKE/TriKE utilization in NK-mediated anti-tumor immunotherapy.
Davis ZB; Vallera DA; Miller JS; Felices M
Semin Immunol; 2017 Jun; 31():64-75. PubMed ID: 28882429
[TBL] [Abstract][Full Text] [Related]
20. Incorporation of a Novel CD16-Specific Single-Domain Antibody into Multispecific Natural Killer Cell Engagers With Potent ADCC.
van Faassen H; Jo DH; Ryan S; Lowden MJ; Raphael S; MacKenzie CR; Lee SH; Hussack G; Henry KA
Mol Pharm; 2021 Jun; 18(6):2375-2384. PubMed ID: 33999642
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
